RBC Capital Maintains Outperform on Insmed, Lowers Price Target to $195

Benzinga · 2d ago
RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $215 to $195.